Chike Agbasi

Providing information regarding modernization of Canada Bread’s compliance program, consistent with Competition Act and related provisions.

Funding for staffing, research and equipement.

Arranging meetings and outreach to public office holders to discuss with them issues related to Catholic Education.

Goderich Port Management Corp. is seeking funding for the Goderich Harbour Wharf Expansion project.

ADVOCATE FOR IMPROVED AWARENESS, PREVENTION AND MANAGEMENT OF WOMEN'S HEART AND BRAIN HEALTH RISK FACTORS THROUGH BILL S-243, AN ACT TO ESTABLISH A NATIONAL FRAMEWORK FOR WOMEN'S HEALTH IN CANADA ADVOCATE FOR A MODERNIZED CHARITABLE TAXATION FRAMEWORK THAT STRENGTHENS CHARITIES AND THEIR ABILITY TO MOBILIZE RESOURCES FOR THE BENEFIT OF CANADIANS. FINALIZE REGULATIONS TO RESTRICT VAPE FLAVOURS (INCLUDING MINT/MENTHOL); INTRODUCE PLAIN AND STANDARDIZED PACKAGING FOR VAPING PRODUCTS; INCREASE TOBACCO AND VAPE TAXES; IMPLEMENT A TOBACCO COST RECOVERY FEE; PROTECT EXISTING NICOTINE POUCH REGULATIONS; BAN INTERNET/ONLINE SALES FOR TOBACCO AND E-CIGARETTES; PROHIBIT THE SALE OF TOBACCO PRODUCTS AMONGST INDIVIDUALS BORN BEFORE A DETERMINED YEAR; INCREASE THE MINIMUM LEGAL AGE OF SALE FOR TOBACCO AND VAPING PRODUCTS TO 21 YEARS OF AGE. SUPPORT POLICIES THAT ELIMINATE FINANCIAL BARRIERS TO SPORT PARTICIPATION FOR CHILDREN AND YOUTH, WHILE ENSURING SPORT PARTICIPATION FUNDING IS ROLLED OUT IN AN ACCESSIBLE, EQUITABLE, AND INCLUSIVE MANNER. ADVOCATE FOR GOVERNMENT ACTION TO REDUCE THE CONSUMPTION OF, AND HARMS ASSOCIATED WITH, ULTRA-PROCESSED FOODS. ADVOCATE FOR AND FUND EQUITABLE ACCESS TO PALLIATIVE CARE PROGRAMS FOR CANADIANS, INCLUDING EQUITY-SEEKING GROUPS. INTRODUCTION OF A NATIONAL PHARMACARE PROGRAM IMPLEMENT REGULATIONS TO RESTRICT COMMERCIAL MARKETING OF UNHEALTHY FOODS AND BEVERAGES TO CHILDREN IMPLEMENT A TAX ON SUGARY DRINKS. REVENUES FROM SUCH A TAXATION STREAM SHOULD BE USED TO SUBSIDIZE HEALTHY EATING INITIATIVES FUND PUBLIC AWARENESS FOR IMPROVED USE OF DEFIBRILLATORS AND CPR. ADVOCATE FOR A TAX-EXEMPTION ON THE SALE OF DEFIBRILLATORS. ENSURE THAT THE DEDICATED FEDERAL ACTIVE TRANSPORTATION INFRASTRUCTURE FUND BECOMES A PERMANENT ENVELOPE IN CANADA'S INFRASTRUCTURE FUNDING.

Development of Health Emergency Readiness Canada agency, and role in promoting development life sciences sector. Subsequent Entry Biologics (SEBs): the need for regulatory amendments to facilitate their approval. Research and Development (R&D): Input on Canada's clinical trial approval and implementations processes; Investing in Canada in R&D. Proposed national pharmacare: Specifically, government’s intention to introduce a national pharmacare program. Modernization of Food & Drug Act: support for proposed regulatory changes, modernization and international harmonizations with other regulatory bodies (European Medicines Agency/U.S. Food and Drug Administration). Input into the Patented Medicines Price Review Board evaluation of annual R&D investments by companies in Canada based on Scientific Research and Experimental Development (SR&ED) tax rules. Working with PMPRB and legislators to ensure appropriate measures of R&D investment are in place. Incentives and programs to attract and support manufacturing activities in Canada Health Canada and the Patented Medicine Prices Review Board(PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations. Health Canada's enforcement of Canada's Food and Drugs Act and Regulations as they relate to the cross border sale of drugs to the United States. COVID-19: Regarding the development of a COVID-19 vaccine & policies and related to the COVID-19 pandemic. Comprehensive Economic Trade Agreement with Europe (CETA) and pharmaceutical intellectual property protection. Communications regarding the maintenance of domestic supply of essential drug products. Canadian Drug Agency: Specifically, the mandate and creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives. Canada-United States-Mexico Agreement (CUSMA) and pharmaceutical intellectual property protection. Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement. An amendment to the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations") regarding the right to appeal.

Seek increased support for entrepreneurs and startups in a range of sectors—from health and cleantech to finance and education—helping them grow and scale into global market leaders by providing expert advice Seek increased access to funding to support innovation companies at all stages of their growth. Collaborating with the Government of Canada on how to commercialize innovation businesses of the future, and making a positive difference in the lives of Canadians and others around the world.